Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 3, 2010, Pages 233-237

  Nam, Eun Ji ^a   Kim, Jae Wook ^b   Kim, Jae Hoon ^a   Kim, Sunghoon ^a   Kim, Sang Wun ^a   Jang, Si Young ^a   Lee, Dae Woo ^a   Jung, Yong Wook ^a   Kim, Young Tae ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

Author keywords

Belotecan; Cisplatin; CKD 602; Combination therapy; Recurrent ovarian cancer

Indexed keywords

BELOTECAN; CISPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEMALE; FOOD INTAKE; HERPES SIMPLEX; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERKALEMIA; ILEUS; INFECTION; MAJOR CLINICAL STUDY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PERCEPTION DEAFNESS; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77953335343     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181a650bc     Document Type: Article

References (18)

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
2. Marsden DE, Friedlander M, Hacker NF. Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol. 2000;19:11-19.
3. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099-2106.
4. Lee JH, Lee JM, Kim JK, et al. Antitumor activity of 7-[2-(N- isopropylamino) ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res. 1998;21:581-590.
5. Lee HP, Seo SS, Ryu SY, et al. Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. Gynecol Oncol. 2008;109: 359-363.
6. Lee DH, Kim SW, Bae KS, et al. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer. Clin Cancer Res. 2007;13: 6182-6186.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
8. Gronlund B, Hogdall C, Hilden J, et al. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol. 2004;22:4051-4058.
9. Rustin GJ. Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials. J Clin Oncol. 2003;21:187-193.
10. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183-2193. (Pubitemid 27251118)
11. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998;16:3345-3352.
12. McGuire WP, Blessing JA, Bookman MA, et al; A Gynecologic Oncology Group Study. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma:. J Clin Oncol. 2000;18:1062-1067.
13. Matsumoto K, Katsumata N, Yamanaka Y, et al. The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol. 2006;100:412-416.
14. Bodurka DC, Levenback C, Wolf JK, et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol. 2003;21:291-297.
15. Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14:195-208.
16. Cantu MG, Buda A, Parma G, et al. Randomized controlled trial of singleagent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinumbased regimens. J Clin Oncol. 2002;20:1232-1237.
17. Armstrong DK. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist. 2004;9:33-42.
18. Takeuchi S, Takamizawa H, Takeda Y, et al. An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers[in Japanese]. Gan To Kagaku Ryoho. 1991;18:579-584.